Disease · MONDO_0001208
acute respiratory failure
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. acute respiratory failure. Diseases, record MONDO_0001208. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0001208
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Highest stage of its drugs
- Phase 3, for 14 of its 46 drugs, from ClinicalTrials.gov and TTD
- Open Targets
Drugs46
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| DEXMEDETOMIDINE | CHEMBL778 | Small molecule | Phase 3 | ClinicalTrials.gov | 4 | 4 | 4 | Drugs and targets |
| AVIPTADIL | CHEMBL1981592 | Protein | Phase 3 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| KETAMINE | CHEMBL742 | Small molecule | Phase 3 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| REMDESIVIR | CHEMBL4065616 | Small molecule | Phase 3 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| ACETAMINOPHEN | CHEMBL112 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| ALMITRINE | CHEMBL1183717 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| FENTANYL | CHEMBL596 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| FUROSEMIDE | CHEMBL35 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| ISAVUCONAZOLE | CHEMBL409153 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| KETOROLAC | CHEMBL469 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
1 to 10 of 46
See all 46 drugsTargets81
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| GABRA1 | GABA-A receptor; anion channel | 3 | GABA-A receptor; anion channel positive allosteric modulator | Phase 3 | https://conductscience.org/library/genes/2554 | Drugs and targets |
| GABRA2 | GABA-A receptor; anion channel | 3 | GABA-A receptor; anion channel positive allosteric modulator | Phase 3 | https://conductscience.org/library/genes/2555 | Drugs and targets |
| GABRA3 | GABA-A receptor; anion channel | 3 | GABA-A receptor; anion channel positive allosteric modulator | Phase 3 | https://conductscience.org/library/genes/2556 | Drugs and targets |
| GABRA4 | GABA-A receptor; anion channel | 3 | GABA-A receptor; anion channel positive allosteric modulator | Phase 3 | https://conductscience.org/library/genes/2557 | Drugs and targets |
| GABRA5 | GABA-A receptor; anion channel | 3 | GABA-A receptor; anion channel positive allosteric modulator | Phase 3 | https://conductscience.org/library/genes/2558 | Drugs and targets |
| GABRA6 | GABA-A receptor; anion channel | 3 | GABA-A receptor; anion channel positive allosteric modulator | Phase 3 | https://conductscience.org/library/genes/2559 | Drugs and targets |
| GABRB1 | GABA-A receptor; anion channel | 3 | GABA-A receptor; anion channel positive allosteric modulator | Phase 3 | https://conductscience.org/library/genes/2560 | Drugs and targets |
| GABRB2 | GABA-A receptor; anion channel | 3 | GABA-A receptor; anion channel positive allosteric modulator | Phase 3 | https://conductscience.org/library/genes/2561 | Drugs and targets |
| GABRB3 | GABA-A receptor; anion channel | 3 | GABA-A receptor; anion channel positive allosteric modulator | Phase 3 | https://conductscience.org/library/genes/2562 | Drugs and targets |
| GABRD | GABA-A receptor; anion channel | 3 | GABA-A receptor; anion channel positive allosteric modulator | Phase 3 | https://conductscience.org/library/genes/2563 | Drugs and targets |
1 to 10 of 81
See all 81 targetsTrials32
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 2 more are not shown, since the checks do not confirm them.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04393038 | ABX464 in Treating Inflammation and Preventing Acute Respiratory Failure in Patients With COVID-19 | Phase 2/3 | 509 | 2025-11-26 | COVID-19 | OBEFAZIMOD | Its record names the disease | ClinicalTrials.gov |
| NCT06729606 | Aviptadil for Severely Ill Inpatients With COVID-19 (An ACTIV-3b/TESICO Treatment Trial) | Phase 3 | 471 | 2025-10-09 | Covid19 | AVIPTADIL | Its record names the disease | ClinicalTrials.gov |
| NCT06729593 | Remdesivir for Severely Ill Inpatients With COVID-19 (An ACTIV-3b/TESICO Treatment Trial) | Phase 3 | 87 | 2025-10-09 | Covid19 | REMDESIVIR | Its record names the disease | ClinicalTrials.gov |
| NCT00871624 | Efficacy and Safety of Dexmedetomidine During Non-Invasive Positive Pressure Ventilation | Phase 2 | 36 | 2015-12-07 | Acute Respiratory Failure | DEXMEDETOMIDINE | Its record names the disease | ClinicalTrials.gov |
| NCT01938079 | Pharmacokinetic Alterations During ECMO | Not applicable | 20 | 2016-09-29 | Acute Respiratory Failure | KETAMINE | Its record names the disease | ClinicalTrials.gov |
| NCT04505592 | Tenecteplase in Patients With COVID-19 | Phase 2 | 13 | 2023-04-06 | COVID-19, Respiratory Failure, ARDS | TENECTEPLASE | Its record names the disease | ClinicalTrials.gov |
| NCT05057221 | Safety, Tolerability and Efficacy of Uproleselan (GMI-1271) in Patients With COVID-19 Pneumonia | Phase 1/2 | 6 | 2023-07-10 | COVID-19 Pneumonia | UPROLESELAN | Its record names the disease | ClinicalTrials.gov |
| NCT04842292 | Nebulized Heparin for COVID19-associated Acute Respiratory Failure | Phase 2 | 2 | 2022-10-18 | Covid19 | HEPARIN | Its record names the disease | ClinicalTrials.gov |
| NCT04488081 | I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill Patients | Phase 2 | 1,500 | COVID-19 | APREMILAST, AVIPTADIL, CELECOXIB, CENICRIVIROC, CYCLOSPORINE, CYPROHEPTADINE, DEXAMETHASONE, DORNASE ALFA, FAMOTIDINE, IC14, ICATIBANT, IMATINIB MESYLATE, NARSOPLIMAB, REMDESIVIR | Its record names the disease | ClinicalTrials.gov | |
| NCT06259565 | Non-invasive Ventilation and Dexmedetomidine in Critically Ill Adults | Phase 3 | 846 | Non-Invasive Ventilation | DEXMEDETOMIDINE | Its record names the disease | ClinicalTrials.gov |
1 to 10 of 32
See all 32 trialsComparisons in its trials25
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| ABX464 vs Placebo: deaths from any cause | 6 of 335 | 4 of 170 | 505 | NCT04393038 | Trial comparisons |
| ABX464 vs Placebo: serious adverse events | 36 of 335 | 20 of 170 | 505 | NCT04393038 | Trial comparisons |
| Aviptadil + SOC vs Placebo + SOC: Number of Participants With a Safety Outcome Through Day 28 | 181 of 231 | 172 of 230 | 461 | NCT06729606 | Trial comparisons |
| Aviptadil + SOC vs Placebo + SOC: Number of Participants Who Died Through Day 180 | 90 of 231 | 86 of 230 | 461 | NCT06729606 | Trial comparisons |
| Aviptadil + SOC vs Placebo + SOC: deaths from any cause | 90 of 231 | 86 of 230 | 461 | NCT06729606 | Trial comparisons |
| Aviptadil + SOC vs Placebo + SOC: Number of Participants With a Safety Outcome Through Day 5 | 146 of 231 | 129 of 230 | 461 | NCT06729606 | Trial comparisons |
| Aviptadil + SOC vs Placebo + SOC: Number of Participants Who Died Through Day 90 | 86 of 231 | 83 of 230 | 461 | NCT06729606 | Trial comparisons |
| Aviptadil + SOC vs Placebo + SOC: serious adverse events | 25 of 231 | 23 of 230 | 461 | NCT06729606 | Trial comparisons |
| ABX464 vs Placebo: Rate of Patients Hospitalized | 23 of 203 | 11 of 102 | 305 | NCT04393038 | Trial comparisons |
| Remdesivir + SOC vs Placebo + SOC: Number of Participants With a Safety Outcome Through Day 28 | 36 of 44 | 34 of 43 | 87 | NCT06729593 | Trial comparisons |
1 to 10 of 25
See all 25 comparisons in its trialsPapers from its trials13
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0001208
GET https://conductscience.org/api/diseases/v1/MONDO_0001208/drugs?page=2